Study: NCT02366728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unpulsed DCs
Description: Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td
Description: Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Description: 2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111In-labeled DCs
Description: 111In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10\^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111In-labeled DCs
Description: 111In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10\^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.